Navigation Links
TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
Date:5/17/2013

BOSTON, May 17, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest update for their competitive landscape map for the Chronic Kidney Disease (CKD) market. This particular landscape highlights over 90 international companies with drugs and devices currently on the market and in development addressing CKD and its sequelae.

(Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO )

Topics include:

  • hypertension - renal denervation
  • diabetic nephropathy - antifibrotics
  • glomerular nephritis – biologics targeting immune complexes
  • polycystic kidney disease – small molecule inhibitors
  • anemia – hepcidin inhibitors
  • hyperkalemia – safer agents
  • mineral and bone disease – cost saving strategies

TechAtlas' analysts have evaluated each technology according to the parameters that dictate their commercial competitiveness, including benefit/risk, cost, convenience, and reimbursement dynamics (e.g., exposure to bundling). For example, non-calcium-based phosphate binders will compete on price as oral drugs enter the dialysis bundle, but certain iron-based agents will have an advantage since they also reduce the need for expensive anemia drugs.  Among future anemia agents, injectable antibodies and RNAi targeting hepcidin will have different times to onset of action, and both will compete against the more convenient oral HIF-PH inhibitors. However, all of these anemia therapies will face pricing pressure in a bundled dialysis environment and will be better received for treating anemia in pre-dialysis patients but only in certain geographies.

The TechAtlas map graphically presents every CKD-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs.  This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the nephrology community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.

TechAtlas Group's current subscribers have reported that their researchers, BD analysts, and executives have used it to guide their business development efforts, R&D resource allocation, and competitive intelligence.

Some of the 90+ companies featured on the TechAtlas Chronic Kidney Disease landscape include: AbbVie, Amgen, Astellas, FibroGen, Fresenius, Johnson & Johnson, Keryx, and ZS Pharma.

For further information on obtaining a copy of this report through an annual subscription, please consult our website:

http://www.techatlasgroup.com/order.html

About TechAtlas Group

TechAtlas Group, LLC brings a novel, multi-dimensional, visually stimulating approach to decision makers who are already flooded with data and information but are seeking context and actionable insight to guide their resource allocation for R&D and commercial activities. Founded in 2011, TechAtlas Group, LLC is headquartered in Boston, MA.  Their large team of PhDs is trained to analyze the viability and commercial competitiveness of a variety of technologies and distill their insights into a visual landscape.  As each field evolves, the maps are updated and issued to subscribers.  Their mission is to convey in one dynamic diagram what has conventionally been crammed into a static 100-page report.


'/>"/>
SOURCE TechAtlas Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hemp, Inc. Signs Letter of Intent with One of Chinas Largest Agricultural Producers, Yasheng Group
2. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
3. Apexus Answers Offers New Service: Live Scheduled 340B Group Chat
4. The MED Group Announces New Agreement with CareCentrix Effective May 1, 2013
5. ASSA ABLOY Door Group Announces RF Shielding Openings
6. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
7. Behavioral Health Group (BHG) Outpatient Opioid Treatment Centers Offer New Medication Option for Patients
8. Hobart Group Holdings Marks 10th Anniversary With Multiple Milestones
9. Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors
10. Thorne Research and YouCare Pharmaceutical Group Announce Joint Venture Deal to Market Nutritional Supplements in China
11. Industry Group To Vow That Boston Terror Attack Victims "Will Walk And Run Again"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc. and SOINN ... in 2016, in which Socionext extracts and delivers ... companies achieved initial results in reading ultrasound images ... Brain SOINN. The results will be introduced at ... 19-21, at booths 4505 & 4507. ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers of Happy ... their novel lifesaving device for the everyday use of parents worldwide. It is ... to read a child’s vital signs, and detect unusual symptoms or physical patterns. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research ... of this type of healthcare model in the diagnosis and treatment of brain ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the Renaissance ... program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish we ... entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. Ted ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to ... Navigate Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 ... CONTACT USA, and former member of the American Association of Christian Counselors. Rachel ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, ... neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announced it ... as the product advances towards regulatory and clinical phases. , "This is another ...
Breaking Medicine News(10 mins):